These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1546564)

  • 1. [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
    Wada S; Yasumoto R; Kashihara N; Kishimoto T; Maekawa M; Hayahara N; Kawakita J; Nishijima T; Morikawa Y; Horii A
    Hinyokika Kiyo; 1992 Jan; 38(1):19-24. PubMed ID: 1546564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A randomized controlled study to compare 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur) for the prevention of post-operative recurrence of bladder cancer].
    Misaki T; Hisazumi H; Sakai A; Nakamura T; Kanda S; Mikawa I; Miyagi T; Katsumi T; Orito M; Kawaguchi K
    Hinyokika Kiyo; 1985 Jul; 31(7):1233-41. PubMed ID: 3933287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study on prophylaxis of diacetyl-glucaro-(1-4) (6-3) dilactone for recurrence of bladder cancer].
    Isomatsu Y; Kaburagi Y; Jinbo S; Nashimo T; Miki M; Yamanaka H
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):1958-62. PubMed ID: 6614934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer.
    Iwagaki H; Tanaka N; Esato K; Kaibara N; Sano K; Dohi K; Nakamura T; Nakasato H; Orita K
    Anticancer Res; 2000; 20(5C):3727-34. PubMed ID: 11268446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
    Obata K; Ohashi Y; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S88-92. PubMed ID: 7994795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection.
    Iwagaki H; Tanaka N; Esato K; Kaibara N; Sano K; Dohi K; Toge T; Nakamura T; Nakasato H; Orita K
    Anticancer Res; 2001; 21(6A):4163-8. PubMed ID: 11911312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.
    Ueda T; Iguchi A; Sagiyama K; Osada Y; Ariyoshi A; Omoto T; Kumazawa J
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S81-4. PubMed ID: 3664948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diacetyl-glucaro-(1 leads to 4) (6 leads to 3)-dilactone (SLA) for prevention of bladder tumor recurrence].
    Shiraishi T; Nihira H
    Hinyokika Kiyo; 1970 Oct; 16(10):586-92. PubMed ID: 5529995
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
    Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
    Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
    Housset M; Maulard C; Chretien Y; Dufour B; Delanian S; Huart J; Colardelle F; Brunel P; Baillet F
    J Clin Oncol; 1993 Nov; 11(11):2150-7. PubMed ID: 8229129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
    Peyromaure M; Slama J; Beuzeboc P; Ponvert D; Debré B; Zerbib M
    Urology; 2004 Jan; 63(1):73-7. PubMed ID: 14751352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylactic effect of UFT on the recurrence of bladder cancer].
    Naito K; Hisazumi H; Saka A; Nakamura T; Kanda S; Mikawa I; Ejiri S; Miyagi T; Katsumi T; Kitagawa K
    Hinyokika Kiyo; 1990 Apr; 36(4):487-94. PubMed ID: 2116083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of 2,5-DI-O-acetyl- -D-gluca ro- (1-4) (6-3)-dilactone (SLA) to the bladder tumor, with special reference to its effect on frequency of tumor recurrences.
    Ichikawa T
    J Urol; 1972 Oct; 108(4):571-6. PubMed ID: 4654258
    [No Abstract]   [Full Text] [Related]  

  • 16. [A study of prophylaxis for recurrence of bladder tumor. Some statistical and experimental studies on the long term administration of -glucuronidase inhibitor (2,5-di-o-acetyl, D-glucaro(1-4)(6-3) dilactone) to patients of bladder tumor].
    Katayama Y
    Nihon Hinyokika Gakkai Zasshi; 1972 Nov; 63(11):951-71. PubMed ID: 4675186
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of 1-hexylcarbamoyl-5-fluorouracil on development of rat urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Ozono S; Iwata H; Tsunemi K; Takahashi S; Matsuki H; Sasaki K; Hirao Y; Okajima E
    Jpn J Exp Med; 1988 Jun; 58(3):123-7. PubMed ID: 3184501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
    Naito S; Iguchi A; Sagiyama K; Ariyoshi A; Osada Y; Omoto T; Kuriya N; Kumazawa J
    Int J Urol; 1997 Jul; 4(4):352-7. PubMed ID: 9256323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of post operative maintenance chemotherapy against ovarian cancer].
    Sawada M; Ozaki M; Hongo J; Hirota Y; Inagaki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jul; 39(7):1115-20. PubMed ID: 3611882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.